Post job

Explore jobs

Find specific jobs

Explore careers

Explore professions

Best companies

Explore companies

ONL Therapeutics CEO and leadership

Zippia score 3.5
OverviewRevenue

Reviews

CEO & Executives

ONL Therapeutics CEO and executives

Executive Summary. Based on our data team's research, David Esposito is the ONL Therapeutics's CEO. ONL Therapeutics has 28 employees, of which 12 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The ONL Therapeutics executive team is 42% female and 58% male.
  • 64% of the management team is White.
  • 6% of ONL Therapeutics management is Hispanic or Latino.
  • 10% of the management team is Black or African American.
Work at ONL Therapeutics?
Share your experience

Rate ONL Therapeutics' leadership communication with employees.

Zippia waving zebra
Name & TitleBio
David Esposito

President & Chief Executive Officer

David Esposito's LinkedIn

David is an experienced healthcare CEO and combat veteran. David has built and scaled multiple healthcare companies that resulted in successful exits.- CEO: Armune BioScience (sold to Exact Sciences [EXAS] Dec. 2017).- US President: Phadia US/AB (sold to Thermo Fisher Scientific [TMO] Sept. 2011).

David Zacks

Chief Scientific Officer, Executive

David Zacks is a Co-Founder/CSO at ONL THERAPEUTICS INC. He has worked as Interim CEO/Managing Director at ONL THERAPEUTICS INC. David attended Albert Einstein College of Medicine.

David M. Kleinman

CMO

David M. Kleinman is a CMO at ONL THERAPEUTICS INC.

Andrew Kocab

Board Member

Bill Burns

Board Member

Linda Johnson

Senior Vice President Operations, VP

Mark E. Hooper

Chairman of The Board

Stella M. Robertson

Board Member

Connie Chang

Chief Operating Officer

Cynthia L. Grosskreutz

Board Observer

Do you work at ONL Therapeutics?

Does leadership effectively guide ONL Therapeutics toward its goals?

ONL Therapeutics jobs

ONL Therapeutics founders

Name & TitleBio
David Esposito

President & Chief Executive Officer

David Esposito's LinkedIn

David is an experienced healthcare CEO and combat veteran. David has built and scaled multiple healthcare companies that resulted in successful exits.- CEO: Armune BioScience (sold to Exact Sciences [EXAS] Dec. 2017).- US President: Phadia US/AB (sold to Thermo Fisher Scientific [TMO] Sept. 2011).

David Zacks

Chief Scientific Officer, Executive

David Zacks is a Co-Founder/CSO at ONL THERAPEUTICS INC. He has worked as Interim CEO/Managing Director at ONL THERAPEUTICS INC. David attended Albert Einstein College of Medicine.

David M. Kleinman

CMO

David M. Kleinman is a CMO at ONL THERAPEUTICS INC.

ONL Therapeutics board members

Name & TitleBio
David Esposito

President & Chief Executive Officer

David Esposito's LinkedIn

David is an experienced healthcare CEO and combat veteran. David has built and scaled multiple healthcare companies that resulted in successful exits.- CEO: Armune BioScience (sold to Exact Sciences [EXAS] Dec. 2017).- US President: Phadia US/AB (sold to Thermo Fisher Scientific [TMO] Sept. 2011).

David Zacks

Chief Scientific Officer, Executive

David Zacks is a Co-Founder/CSO at ONL THERAPEUTICS INC. He has worked as Interim CEO/Managing Director at ONL THERAPEUTICS INC. David attended Albert Einstein College of Medicine.

Andrew Kocab

Board Member

Bill Burns

Board Member

Linda Johnson

Senior Vice President Operations, VP

Mark E. Hooper

Chairman of The Board

Stella M. Robertson

Board Member

ONL Therapeutics executives FAQs

Most in demand jobs

Updated November 18, 2022

Zippia gives an in-depth look into the details of ONL Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ONL Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at ONL Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ONL Therapeutics. The data presented on this page does not represent the view of ONL Therapeutics and its employees or that of Zippia.

ONL Therapeutics may also be known as or be related to ONL Therapeutics, ONL Therapeutics Inc and ONL Therapeutics, Inc.